登录 查看组织和合同定价。
选择尺寸
关于此项目
NACRES:
NA.41
UNSPSC Code:
12352203
Species reactivity:
(Akkermancia muciniphila)
Technique(s):
immunoblotting: 1:500-1:1000 using Akkermansia muciniphila lysate
Application:
—
Citations:
-
biological source
rabbit
antibody form
IgG fraction of antiserum
antibody product type
primary antibodies
form
liquid
species reactivity
(Akkermancia muciniphila)
packaging
pkg of 100 μL, pkg of 25 μL
concentration
~1 mg/mL
technique(s)
immunoblotting: 1:500-1:1000 using Akkermansia muciniphila lysate
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
General description
Akkermansia muciniphila is a Gram negative, oval shaped, non-motile, non-spore forming strictly anaerobic bacteria.1 A. muciniphila colonized in the mucus layer of the human intestine niche. A muciniphila inhabits the gastrointestinal tracts of most of healthy adults and represents 1-4% of the total fecal microbiota starting from early life.2 It is one of the top 20 most abundant species detectable in the human gut.3 It was found that A. muciniphila abundance in the gut was correlated to a healthy intestine and inversely correlated to many disease conditions.2 In comparison to healthy controls, A. muciniphila levels were low in intestinal disorders, such inflammatory bowel disease IBD, but also in other conditions, such as autism, atopy, and obesity.2,5-8 Therefore, A. muciniphila was suggested to serve as a marker of healthy intestine.
In addition, goring research identified A. muciniphila as a promising potential probiotic that can be administrated for the treatment of diseases such as, colitis, metabolic syndromes, immune diseases and cancer. However more research is needed to verify the safety of oral administration of A. muciniphila in humans.3
In addition, goring research identified A. muciniphila as a promising potential probiotic that can be administrated for the treatment of diseases such as, colitis, metabolic syndromes, immune diseases and cancer. However more research is needed to verify the safety of oral administration of A. muciniphila in humans.3
Biochem/physiol Actions
A. muciniphila is able to degrade mucin, a key mucus component, using the enzymes sialidase and fucosidase, and utilize it as a source of carbon and nitrogen.2 Mucin degradation by A. muciniphila results in the production of short-chain fatty acids (SCFA), that become available metabolites to the host and also can stimulate the host immune system. Moreover, SCFA promotes the growth and metabolic activity of mucus- associated gut microbiota preventing the pathogenic bacteria from reaching the intestinal cells.4
Anti-Akkermansia muciniphila antibody recognizes A. muciniphila lysate and whole dead bacteria.
Physical form
Supplied as a solution in 0.01 M phosphate buffered saline pH 7.4, containing 15 mM sodium azide as a preservative.
Preparation Note
For continuous use, store at 2-8°C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilution samples should be discarded if not used within 12 hours.
Disclaimer
Unless otherwise stated in our catalog our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到合适的产品?
试试我们的产品选型工具.
存储类别
12 - Non Combustible Liquids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
常规特殊物品
低风险生物材料
此项目有
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持